Rozanolixizumab + Monoclonal Antibodies Interaction
Moderateinteraction on record
Description
Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for reduced effectiveness.
Mechanism
Competition for human neonatal Fc receptor (FcRn) binding
Source: NLP:rozanolixizumab